🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,265 results for “Gan” Clear

  1. BinD19

    The First People's Hospital of Lianyungang

    Relapsed B-cell Acute Lymphoblastic Leukemia

    phase 2 mab active

    1 trial

  2. Blinatumomab

    The First People's Hospital of Lianyungang

    B-cell Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  3. Blinatumomab plus Reduced-dose Chemotherapy

    The First People's Hospital of Lianyungang

    Precursor B-Cell Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  4. Brimo PS DDS®

    Allergan Pharmaceuticals International Limited

    Patients Who Participated in an Intravitreal Brimo PS DDS® Study

    phase 2 small molecule completed

    1 trial

  5. Budesonide

    LIGAND PHARMACEUTICALS INC

    Seasonal Allergic Rhinitis

    phase 2 small molecule completed

    1 trial

  6. Budesonide + Azelastine

    LIGAND PHARMACEUTICALS INC

    Seasonal Allergic Rhinitis

    phase 2 small molecule completed

    1 trial

  7. C225 (cetuximab)

    The First People's Hospital of Lianyungang

    Nasopharyngeal Carcinoma

    phase 2 small molecule completed

    1 trial

  8. CAR T-cell therapy

    The First People's Hospital of Lianyungang

    Acute Lymphoblastic Leukemia With Failed Remission

    phase 2 mab active

    1 trial

  9. CAR-BCMA T Cells

    The First People's Hospital of Lianyungang

    Multiple Myeloma

    phase 2 mab active

    1 trial

  10. CAR-T

    The First People's Hospital of Lianyungang

    Leukemia, Lymphocytic, Chronic, B-Cell

    phase 2 mab active

    1 trial

  11. CAR-T Cells

    The First People's Hospital of Lianyungang

    Lung Neoplasm Malignant

    phase 2 mab active

    1 trial

  12. CAR-T treatment

    The First People's Hospital of Lianyungang

    Multiple Myeloma

    phase 2 mab active

    1 trial

  13. CD19 CAR-T cells

    The First People's Hospital of Lianyungang

    Acute Lymphoblastic Leukemia

    phase 2 mab active

    1 trial

  14. CD19 CAR-T cells and CD19 positive feeder T cells

    The First People's Hospital of Lianyungang

    Acute Lymphoblastic Leukemia in Remission

    phase 2 mab active

    1 trial

  15. CE-Iohexol

    LIGAND PHARMACEUTICALS INC

    Contrast-induced Nephropathy

    phase 2 small molecule terminated

    1 trial

  16. CIK

    The First People's Hospital of Lianyungang

    Lung Adenocarcinoma

    phase 2 mab terminated

    1 trial

  17. CM313 (SC)

    The First People's Hospital of Lianyungang

    Pemphigus Disease

    phase 2 small molecule active

    1 trial

  18. CM336 Injection

    The First People's Hospital of Lianyungang

    Autoimmune Bullous Disease

    phase 2 mab active

    1 trial

  19. CMOP±R

    The First People's Hospital of Lianyungang

    NHL

    phase 2 small molecule active

    1 trial

  20. Cadonilimab

    The First People's Hospital of Lianyungang

    Lung Cancer

    phase 2 small molecule active

    1 trial

  21. Cadonilimab

    The First People's Hospital of Lianyungang

    Immunotherapy

    phase 2 small molecule active

    1 trial

  22. Cadonilimab

    The First People's Hospital of Lianyungang

    Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  23. Camrelizumab

    The First People's Hospital of Lianyungang

    Nasopharyngeal Carcinoma

    phase 2 small molecule active

    1 trial

  24. Camrelizumab

    The First People's Hospital of Lianyungang

    Gastric Cancer Stage III

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources